You are here
In this Section
- Major Initiatives
- Medications Development Program
- Underage Drinking Research Initiative
- Fetal Alcohol Spectrum Disorders
- COMBINE Study
- Quetiapine Study
- Collaborative Studies on Genetics of Alcoholism (COGA) Study
- NIAAA-Funded Research Centers
- NIAAA Institutional Research Training Programs
- Other Key Extramural Research Activites
- Guidelines and Resources
- Division of Intramural Clinical and Biological Research
- NIAAA Laboratories
- Laboratory of Behavioral and Genomic Neuroscience
- Laboratory of Clinical and Translational Studies
- LCTS - Office of the Chief
- LCTS - Section of Brain Electrophysiology and Imaging (BEI)
- LCTS - Section of Clinical Assessment and Treatment Evaluation (CATE)
- LCTS - Section on Clinical Psycho-neuroendocrinology and Neuro-psychopharmacology (CPN)
- LCTS - Section on Human Psychopharmacology (HP)
- LCTS - Section of Molecular Pathophysiology (MP)
- Laboratory of Epidemiology and Biometry
- Laboratory for Integrative Neuroscience
- Laboratory of Liver Diseases
- Laboratory of Membrane Biochemistry and Biophysics
- Laboratory of Metabolic Control
- Laboratory of Molecular Physiology
- Laboratory of Molecular Signaling
- Laboratory of Neurogenetics
- Laboratory for Neuroimaging
- Laboratory of Physiologic Studies
- Chemical Biology Research Branch (joint lab with NIDA)
- Office of the Scientific Director
- Office of Laboratory Animal Science (OLAS)
- Research and Training
- Clinical Trials at NIAAA/NIH
- NIAAA Laboratories
COMBINE Study
Data Access Policy, Application and Agreement
COMBINE
A Multisite Trial of Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence
Introduction
The COMBINE Study (often times referred to as COMBINE) is the largest pharmacotherapy trial conducted for alcoholism in the United States, recruiting 1383 alcohol dependent patients, 31% women and 23% ethnic minorities, from 11 sites. This double-blind, randomized placebo-controlled trial evaluated the efficacy of naltrexone and acamprosate, both alone and in combination, in the context of medical management with and without Combined Behavioral Intervention (CBI). CBI is a therapy that integrates aspects of cognitive behavioral therapy, motivational interviewing and 12-step facilitation. The duration of treatment was four months with follow-ups for one year post treatment. There were nine groups including a CBI only group with no pills and no medical management. The main findings were published in JAMA 295:2003-2017, 2006. Other articles either published, or in press, can be found at the COMBINE Study website as indicated below. Individuals requesting the data set for specific analyses are urged to view the website to better understand what has been previously published.
The data set was prepared by staff of the trial’s CoordinatingCenter at the University of North Carolina and reviewed by CSR Incorporated. The project’s website, www.cscc.unc.edu/combine, will carry the most recent information regarding the data set, a list of publications, and other information concerning the trial.
Data Access Application Procedure and Access Policy
Because COMBINE contains individual level data, it is categorized as a controlled access data set. Access will only be provided to research investigators who, along with their institutions, have certified their agreement with the expectations and terms of access detailed in this document.
Qualified researchers should complete (1) the attached Data Access Application form and (2) sign the attached Data Access Agreement. This agreement is designed to protect the integrity of the data set and assure client confidentiality. Note that the signature and concurrence of your authorized institutional official is also required. This is ordinarily the person who signs grant applications. Completed applications may be submitted by e-mail, fax, or mail to:
Raye Z. Litten, Ph.D.
Associate Director
Division of Treatment and Recovery Research
National Institute on Alcohol Abuse and Alcoholism
5635 Fishers Lane, Room 2041
Bethesda , Maryland20892-9304
(Rockville, Maryland20852-1705 for Federal Express)
Tel: (301) 443-0636
Fax: (301) 443-8774
Email: rlitten@mail.nih.gov
